Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Medscape

Hemodynamics improved significantly for patients with obstructive hypertrophic cardiomyopathy who took aficamten, the second myosin inhibitor to reach clinical trials, in a small randomized study.